(Q37947449)

25 August 2017

title

Significant publications on infectious diseases pharmacotherapy in 2010. (English)

1 reference

25 August 2017

0 references

Elizabeth B Hirsch

1

1 reference

25 August 2017

Jessica M Cottreau

2

1 reference

25 August 2017

Judy O Ikwuagwu

3

1 reference

25 August 2017

Katherinet Lusardi

4

1 reference

25 August 2017

John F Mohr

5

1 reference

25 August 2017

Sarah M Rodriguez

6

1 reference

25 August 2017

Dhara N Shah

7

1 reference

25 August 2017

Truc T Tran

8

1 reference

25 August 2017

Houston Infectious Diseases Network

9

1 reference

25 August 2017

publication date

1 November 2011

1 reference

American Journal of Health-System Pharmacy

25 August 2017

published in

1 reference

25 August 2017

volume

68

1 reference

25 August 2017

issue

21

1 reference

25 August 2017

page(s)

2075-2085

1 reference

Significant publications on infectious diseases pharmacotherapy in 2007.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Significant publications on infectious diseases pharmacotherapy in 2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Significant publications on infectious diseases pharmacotherapy in 2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

The CTX-M beta-lactamase pandemic.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae from blood culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110125

31 March 2020

Identifiers

DOI

10.2146/AJHP110125

1 reference

25 August 2017

1 reference